Evaluate the Effect of a Digital Disease Management Tool in DM Patient
Research type
Research Study
Full title
A real-world, point-of-care, randomised, parallel group, open, 6-month clinical study to evaluate the effect of a digital disease management tool in patients with type 2 diabetes mellitus
IRAS ID
193306
Contact name
Nicola Turvey
Contact email
Sponsor organisation
AstraZeneca AB
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 11 months, 2 days
Research summary
Type 2 diabetes mellitus (T2DM) is a disease that develops when cells in the body are unable to produce enough insulin or when insulin that is produced does not work properly. Insulin is a hormone that works as a chemical messenger to help the body use the glucose in the blood to give us energy. It is important that diet, weight and physical activity are carefully managed in patients with T2DM. \nPatient support in various forms can improve adherence to treatment and the meeting of targets in patients with T2DM. According to the recently updated National Institute for Health and Care Excellence (NICE) guidelines, Diabetes Self-Management Education and Support programs, are associated with improved diabetes knowledge, self-care behaviour, and clinical outcomes. In the current technological environment, smart phone-and web portal-based tools have great potential to efficiently assist patients in disease self-management on a daily basis.\nThe aim of the study is to evaluate the effect of a smart phone tool and a web portal tool on the management of T2DM along with the standard of care treatment in participants with T2DM. \nAstraZeneca is the sponsor of this study which will take place in the United Kingdom (UK). It is anticipated that approximately 466 participants will be recruited across the UK. \n
REC name
London - City & East Research Ethics Committee
REC reference
16/LO/0152
Date of REC Opinion
21 Mar 2016
REC opinion
Further Information Favourable Opinion